We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more Skip to Main Content

Editorial Board

EDITOR-IN-CHIEF:

J. P. Donnelly (Nijmegen, The Netherlands)

Donnelly

Current Positions and Research Interests

Dr Donnelly works for the Department of Haematology of the Radboud University Nijmegen Medical Centre. His main interests are the management and diagnosis of infectious complications in haematological malignancies and stem cell transplantation and he has extensive experience in the design, conduct, analysis and reporting of clinical trials. He has been involved in the Journal of Antimicrobial Chemotherapy for many years.

Declaration of Interests

Dr Donnelly has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and a number of pharmaceutical companies: including Astellas, Gilead, Merck and Pfizer. He chairs both the Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer Infectious Diseases Group and the European Aspergillus PCR Initiative – a Working Group of the International Society of Human and Animal Mycology (ISHAM). He is also secretary to the ISHAM, and is a member of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

SENIOR EDITORS

F. K Gould (Newcastle upon Tyne, UK)

Gould
Current Positions and Research Interests

Professor Gould is a Consultant Microbiologist and has been in her present appointment since 1988, working for the NHS Hospital Trust, over two sites within a busy teaching hospital, she is also Regional Microbiologist, Health Protection Agency, with special interest in Healthcare Associated Diseases. Professor Gould has an interest in the diagnosis and treatment of lower respiratory tract infections, and the management of infection in patients with impaired renal function including the diagnosis and treatment of peritonitis in Continuous Ambulatory Peritoneal Dialysis. In addition she has worked closely with the adult and paediatric thoracic transplant programme and is a member of the Infection Council of the International Society of Heart and Lung Transplantation.

Declarations of Interests

Professor Gould has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and a number of pharmaceutical companies: such as AstraZeneca, Astellas, Pfizer and Forest Labs.

A. P. Johnson (London, UK)

A. P. Johnson (2014)

Current Positions and Research Interests

Professor Johnson works for Public Health England (formally UK Health Protection Agency) in London undertaking surveillance of antibiotic resistance. He also teaches on a number of academic courses on aspects of medical microbiology.

Declaration of Interests

Professor Johnson has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and a number of pharmaceutical companies: including AstraZeneca, Janssen-Cilag and Novartis. He is a member of the Prescribing sub-group of the Advisory Committee on Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI).

R. L. Murphy (Chicago, USA)

Murphy

Current Positions and Research Interests

Dr. Rob Murphy is currently the John P. Phair Professor of Infectious Diseases at Northwestern University where he is also Director, Center for Global Health. He holds academic appointments as Visiting Professor of Immunology and Infectious Diseases at Harvard School of Public Health and Professeur Associé de Recherche at the Pierre et Marie Curie Université in Paris.

Dr. Murphy’s primary research interest is in viral infections. His research includes drug development of new antiretroviral drugs, anti-hepatitis agents, therapeutic vaccines, the complications of antiviral therapy and the scale up of therapy for AIDS, tuberculosis and malaria in sub-Saharan Africa. Dr. Murphy is the Principal Investigator for the National Institutes for Allergy and Infectious Diseases (NIAID) Adult AIDS Clinical Trials Group (ACTG) at Northwestern. Within the ACTG he holds leadership positions including membership on the Executive Committee, the governing body of the group, co-chair of the Data Management Committee and membership on the Hepatitis Transformative Science Group. He is a member of multiple medical societies and sits on the boards of several non-profit organizations including the Drucker Family Charitable Trust, the International AIDS Education Project, Objectif Recherche Vaccin SIDA and the Midwest AIDS Foundation, of which he is the founder. International activities and interests include being Principal Investigator for the National Institutes for Health/Fogarty International Center’s AIDS International Training and Research Program based in Nigeria and Mali and the Medical Education Partnership Initiative in Nigeria. He has co-authored more than 240 scientific publications.

Declaration of Interests

Consultant to Gilead Sciences, Merck Pharmaceuticals, Argos Therapeutics; he is a founder and shareholder of InnaVirVax and shareholder of Idenix Pharmaceuticals.

L. Ostrosky-Zeichner (Houston, USA)

L. Ostrosky-Zeichner (Houston, USA)

Current Positions and Research Interests

Dr Ostrosky-Zeichner is currently an associate professor of medicine and epidemiology, associate fellowship program director, and director of the Laboratory of Mycology Research, at the Division of Infectious Diseases of the University of Texas Medical School at Houston. He also serves as medical director for epidemiology for Memorial Hermann Texas Medical Center. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America.

Declaration of Interests

Dr Ostrosky-Zeichner has received grant support and speaks and/or consults for Merck, Pfizer, Astellas, Viracor, GSK, Novadigm, and Gilead and has received grant support from Basilea and Associates of Cape Cod.

J. D. Perry (Newcastle upon Tyne, UK)

Perry

Current Positions and Research Interests

Dr John Perry is a Clinical Microbiologist employed at the Freeman Hospital in Newcastle upon Tyne, UK. He is an Honorary Senior Lecturer at Newcastle University and a Visiting Professor at Northumbria University. He is a member of two BSAC Working Parties: one on susceptibility testing and the other on management of endocarditis. His research interests include diagnostic bacteriology and particularly the design of novel culture media.

Declaration of Interests

He has received funding for Research or Consultancy from diagnostics companies including bioMérieux, Becton Dickinson and Lab M

D. S. Reeves (Bristol, UK)

Reeves

Current Positions and Research Interests

Professor David Reeves retired from the NHS in 1998. After qualifying in medicine, and following posts at the Westminster, Edgware and St Mary’s Hospitals, he was Consultant Medical Microbiologist and Control of Infection Officer of Southmead Hospital for 27 years. He is Honorary Professor of Medical Microbiology, University of Bristol.

His main research interests were the treatment of UTI, evaluating new antibiotics in clinical practice, the development and use of clinical assays of antibiotics, TDM (particularly aminoglycosides), and antibiotic pharmacokinetics. This resulted in some 220 original publications and 120 reviews and book chapters.

He has held a number of positions in the BSAC (founder Council member, Meetings Secretary, General Secretary), and was an Editor of JAC (1985-91), member and chairman of what is now the Editorial Advisory Board (74-96), and Editor-in-Chief (2000-6). He is an Honorary Life member of the BSAC and a former Garrod medallist.

Professor Reeves has edited many supplements for JAC and also a number of books, and still referees regularly for other journals. He recently published a chapter on aminoglycosides in a standard reference work.

Declaration of Interests

Professor Reeves currently has no involvement with industry, although he was a consultant to many companies in the past up to 2008.

S. Schwarz (Neustadt-Mariensee, Germany)

Schwarz

Current Positions and Research Interests

Prof. Dr. med. vet. Stefan Schwarz works in the Institute of Farm Animal Genetics of the Friedrich-Loeffler-Institut (= Federal Research Institute for Animal Health) in Neustadt-Mariensee, Germany. He heads a research group entitled ‘Molecular Microbiology and Antimicrobial Resistance’ and is involved in both surveillance of antimicrobial resistance and analysis of the molecular genetics of antimicrobial resistance. He also teaches various academic courses at the University of Veterinary Medicine Hannover.

Declaration of Interests

Prof. Schwarz has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and a number of pharmaceutical companies including Bayer Animal Health, Boehringer Ingelheim, Elanco Animal Health, Intervet, Pfizer Animal Health, and Schering-Plough. He is a member of the Veterinary Antimicrobial Susceptibility Testing (VAST) subcommittee of the Clinical and Laboratory Standards Institute (CLSI) and the chairman of the working group ‘Antimicrobial Resistance’ of the German Veterinary Medical Society.

A. Tsakris (Athens, Greece)

 	 Tsakris

Current Positions and Research Interests

Athanassios Tsakris graduated as an MD from the Medical School of University of Athens, Greece and completed his training in Medical Microbiology at North Middlesex Hospital, London and the Central Public Health Laboratory, London. He received his PhD degree from the London School of Hygiene and Tropical Diseases, University of London. He is a Fellow in Medical Microbiology and Virology at the Royal College of Pathologists, London.

Prof Tsakris is currently Professor and Head of the Department of Microbiology at the Medical School, University of Athens, Greece. He teaches various undergraduate and postgraduate academic courses at the University of Athens. His major interests include surveillance of multidrug-resistant pathogens and molecular mechanisms of antimicrobial resistance. In addition to being an Editor for the Journal of Antimicrobial Chemotherapy , he also serves on the editorial boards of other microbiology/infectious disease journals.

Declaration of Interests

Prof Tsakris has occasionally received research funding from both academia and pharmaceutical companies.

E. van Duijkeren (Utrecht, The Netherlands)

vanduijkeren

Current Positions and Research Interests

Dr Engeline van Duijkeren works at the Laboratory for Zoonoses and Environmental Microbiology at the National Institute for Public Health and the Environment (RIVM) in Bilthoven, The Netherlands. Her research interests focus on the epidemiology and mechanisms of antimicrobial resistance in staphylococci and Enterobacteriaceae including transmission of zoonotic bacteria between animals and humans.

Declaration of Interests

Research at Dr van Duijkeren’s laboratory is mainly funded by the government and national programmes. Dr van Duijkeren currently has no involvement with industry, but in the past she received research support and consultancy fees from pharmaceutical industry including Pfizer and Intervet/MSD Animal Health. She is a member of the editorial board of Veterinary Microbiology . She is also a member of the Scientific Advisory Group on Antimicrobials (SAGAM) of the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA).

EDITORIAL BOARD

R. Anthony (Amsterdam, The Netherlands)

R. Anthony (Amsterdam, The Netherlands)

Current Positions and Research Interests

Dr Richard Anthony leads the tuberculosis research activities at the Royal Tropical Institute, Amsterdam, The Netherlands. His current research interests include the rapid detection of infection and drug resistance/susceptibility in M. tuberculosis . A particular interest of our department is provision of infectious disease diagnostics in high burden settings.

Declaration of Interests

Research in our laboratory is funded by national programmes, the European Union, and FIND Genève. Additionally we also occasionally perform small research projects funded by commercial partners, for example Philips Research.

D. Ashiru-Oredope (London, UK)

ashiru oredope

Current Positions and Research Interests

Dr Diane Ashiru-Oredope is the Pharmacist Lead for the Antimicrobial Resistance Programme at Public Health England (PHE) and the Department of Health Expert Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI).

An antimicrobial pharmacist by background, she chaired the multiprofessional subgroup that updated the national antimicrobial stewardship toolkit for secondary care – Start Smart then Focus and project led the ARHAI/PHE national Antimicrobial Prescribing and Stewardship Competences.

She is the deputy chair for the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) and Chair of the planning group for European Antibiotic Awareness Day activities in England and the UK Antibiotic Guardian campaign which is underpinned by behavioural science.

Dr Ashiru-Oredope led the development and evaluation of the Antibiotic Guardian campaign and provides significant contributions to AMR-related behaviour insights interventions in PHE. She contributed to the PHE literature review and behavioural analysis on behaviour change and antibiotic prescribing in healthcare settings

Her research interests include Antimicrobial Stewardship, monitoring antimicrobial consumption and behaviour change/insights interventions to tackle antimicrobial resistance

Declarations of Interests

D. Ashiru-Oredope is affiliated with the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London in partnership with PHE.

G. Biagini (Liverpool, UK)

Biagini
Current Positions and Research Interests

Dr Giancarlo Biagini, B.Sc. Ph.D. is a Reader at the Liverpool School of Tropical Medicine, UK. Over the past 10 years at the school, Dr Biagini’s research interests have been in Drug Discovery, Pharmacology, Biochemistry and Physiology of human pathogens, principally Plasmodium falciparum and more recently Mycobacterium tuberculosis .

Declaration of Interests

Dr Biagini holds and has received grant funding from the EU, UK research councils and national and international charitable trusts but has not received any funding from commercial sources.

A. Carattoli (Rome, Italy)

Dr Alessandra Carattoli

Current Positions and Research Interests

Dr Alessandra Carattoli is Research Director in the Department of Infectious, Parasitic and Immune-Mediated Diseases at the Istituto Superiore di Sanità in Rome, Italy. Her research interests include identification and characterization of resistance plasmids in Gram-negatives, bacterial genomics and metagenomics, molecular epidemiology of Escherichia coli, Klebsiella pneumoniae, Salmonella enterica and Acinetobacter baumannii .

Declaration of Interests

Dr Carattoli’s research has been funded by government and national programmes (Italian Ministry of Health, National Council of Research) and the European Union; she received support for a research project by Pfizer.

P. Chandrasekar (Detroit, USA)

P. Chandrasekar (Detroit, USA)

Current Positions and Research Interests

P. H. Chandrasekar serves as Professor of Medicine/Infectious Diseases and is Director of the Infectious Diseases Fellowship Program at Wayne State University, Detroit, Michigan, USA. He also serves as the Chief of the Infectious Diseases section at Karmanos Cancer Institute, Detroit, Michigan. His major interests include management and prevention of infections in cancer patients and stem cell transplant recipients.

Declaration of Interests

Dr Chandrasekar has received research support, honoraria for lectures and consultancy fees from a number of pharmaceutical companies including Astellas, Merck, Pfizer and Enzon.

V. I. Enne (London, UK)

V. I. Enne (London, UK)

Current Positions and Research Interests

Dr Enne works at the Blizard Institute of Cell and Molecular Science, at Queen Mary, University of London. She undertakes research into various aspects of antimicrobial resistance and her interests include: silencing of antibiotic resistance genes; fitness cost of resistance; persistence of resistance in the absence of selection; and molecular mechanisms of resistance. She also teaches on various undergraduate microbiology courses. She is a member of the Editorial Board of the Journal of Antimicrobial Chemotherapy .

Declaration of Interests

Dr Enne currently receives research funding from The Wellcome Trust and has previously received funding from DEFRA and BSAC. She has not received funding from commercial organisations of any kind.

H. J. Field (Cambridge, UK)

H. J. Field (Cambridge, UK)

Current Positions and Research Interests

Dr Field is Reader in Comparative Virology, working at the Veterinary School, University of Cambridge. He is also a Fellow and Director of studies in Medical and Veterinary Sciences at Queens' College, Cambridge. His research focuses on herpes viruses and antiviral agents, especially nucleoside analogues and helicase-primase inhibitors. His publications include original papers and reviews on the effects of antivirals in laboratory infection models and the mechanisms of antiviral resistance.

Declaration of Interests

Dr Field has received research funding or honoraria for lectures or consultancy from academia and a number of pharmaceutical companies, most recently Novartis and AiCuris Co, Germany. He is also Editor-in-Chief for the journal Antiviral Chemistry and Chemotherapy and serves on the Pathology Council for the Royal Society of Medicine.

G. Guaraldi (Modena, Italy)

G. Guaraldi (Modena, Italy)

Current Positions and Research Interests

Giovanni Guaraldi is Assistant Professor of Infectious Diseases at the University of Modena and Reggio Emilia. His primary research interests are lipodystrophy and cardiometabolic complications in patients with HIV infection. Since 2002, he has been the leader of the Metabolic Clinic of Modena University, a multidisciplinary referral clinic where a 3000 HIV patient cohort is monitored for HIV-associated chronic disease. He is the physician in charge of the HIV solid organ transplant centre in Modena where 20 HIV patients have so far received liver or kidney transplants. He is panel member of EACS Guidelines on the Prevention and Management of Metabolic Diseases in HIV.

Declaration of Interests

Giovanni Guaraldi has received research funding or honoraria for lectures or consultancy from both academia and a number of pharmaceutical companies including: Gilead Sciences, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag and Merck.

R. M. Hall (Sydney, Australia)

Professor Ruth Hall

Current Positions and Research Interests

Professor Ruth Hall is in the School of Molecular Bioscience at the University of Sydney, Sydney, Australia. Work in her laboratory focuses on the molecular genetics and genomics of antibiotic resistance in Gram-negative bacteria (Escherichia coli, Salmonella enterica, Klebsiella pneumoniae, Acinetobacter baumannii) with particular interests in the identification, characterization and evolution of regions carrying resistance genes, and the molecular mechanisms that lead to the dissemination of the resistance genes.

Declaration of Interests

Professor Hall’s research has been supported by the government funding from the National Health and Medical Research Council (NHMRC). She has not received any funding from commercial sources.

A. Hill (Liverpool, UK)
Hill

Current Positions and Research Interests

Dr Andrew Hill is a Senior Visiting Research Fellow at Liverpool University. Dr Hill has a first degree from Oxford University and a PhD from the University of Amsterdam. His speciality is the design and analysis of HIV clinical trials. He is working on antiretroviral treatment for developing countries.

Declaration of Interests

Dr. Hill conducts consulting work for Tibotec/Janssen-Cilag, on clinical trials of darunavir and etravirine. He is also the trustee of a UK charity, ‘Living and Loving’ which provides support for children with HIV/AIDS in Thailand.

R. Hope (London, UK)

Hope

Current Positions and Research Interests

Dr Hope works for Public Health England (PHE) (formally UK Health Protection Agency) in London undertaking surveillance of antibiotic resistance and healthcare associated infection. He currently heads the section responsible for the mandatory surveillance of bacteraemia and Clostridium difficile infection in England. Prior to this Russell ran surveillance programmes for the PHE's Antibiotic Resistance Monitoring and Reference Laboratory. Interests are focused on the epidemiology of infections cause by antimicrobial resistant pathogens, artificial intelligence for improved clinical diagnostics and antibiotic resistance mechanisms within the Enterobacteriaceae.

Declaration of Interests

Dr Hope has received support for research projects and/or conference attendance from a number of companies including, Pfizer, Wyeth (now Pfizer), Johnson & Johnson, Novartis, and Smith and Nephew.


M. Hornsey (London, UK)

Hornsey

Current Positions and Research Interests

Mike Hornsey is a Biomedical scientist at Viapath and is currently based in the Infection Sciences Department at King’s College Hospital, London. His current research interests include: mechanisms of resistance to antimicrobial agents of last resort; investigating novel therapeutic strategies for the treatment of infections caused by nosocomial pathogens; development and implementation of rapid diagnostic tools (virology & bacteriology); invertebrate models of infection. He has previously held academic and postdoctoral positions at the University of Roehampton and Queen Mary, University of London, respectively.

Declaration of Interests

Dr Hornsey’s research has been supported by Wyeth (now Pfizer), Astellas Pharma and Basilea Pharmaceutica. He has also received sponsorship to attend conferences from Pfizer.


J. C. Hurley (Melbourne, Australia)

J.C. Hurley (Melbourne, Australia)

Current Positions and Research Interests

James Hurley is an infectious disease physician at Ballarat Health Services and Associate Professor in Medicine at The University of Melbourne, Australia. His main research interests are endotoxin and the mediation of sepsis, methods of meta-analysis, hospital infection control and the epidemiology of nosocomial infections.

Declaration of Interests

James Hurley has not received any funding or honoraria from the industry in the last 10 years, and has no other conflict of interest to declare.

D Jenkins (Leicester, UK)

Jenkins

Current Positions and Research Interests

Dr David Jenkins has been a consultant medical microbiologist in Leicester since 1997 and the lead infection control doctor for University Hospitals of Leicester NHS Trust since 2000. He is also an honorary reader at the University of Leicester Medical School. His clinical work focuses on providing a microbiology service to Glenfield Hospital cardiology, respiratory and intensive care units, including the adult and paediatric extracorporeal membrane oxygenation units. His infection control work includes healthcare infection and antimicrobial stewardship strategy and policy development. He is also involved in developing and delivering infection teaching to Leicester University medical students. Dr Jenkins has served on a number of national working parties producing guidelines on the prevention of healthcare infections due to respiratory pathogens, norovirus and pertussis. He contributed to the English Department of Health Cleaner Hospitals support programme, providing advice to a number of hospitals with high rates of C. difficile and MRSA infections.
His research focuses on reducing healthcare infections through improving infection prevention practice.

Declarations of Interest

Dr Jenkins is a director of Healthcare Infection Prevention Limited. He has received speaker and advisory board fees for Astellas and MSD. He has written expert witness reports on healthcare infection claims for a number of legal firms.

P. Kanki (Boston, USA)

P Kanki

Current Positions and Research Interests

Phyllis Kanki DVM ScD is a Professor of Immunology & Infectious Disease at the Harvard School of Public Health. She studies the pathogenesis and molecular epidemiology of HIV in Africa. For several decades, she led AIDS research programs in Senegal, focusing on the identification and attenuated biology of HIV-2, cross protection between HIV-2 and HIV-1, and differential disease development by HIV genotypes. From 2000-2006, Dr. Kanki directed the AIDS Prevention Initiative in Nigeria (APIN), a program she created with a grant from the Gates Foundation. From 2004 - 2013, Dr. Kanki served as the principal investigator for the Harvard PEPFAR program, which provided training, capacity building and targeted evaluation in three partner countries (Nigeria, Tanzania, Botswana). The program provided antiretroviral therapy (ART) to over 160,000 patients along with significant research findings. She directs HSPH’s partnership with five universities in the Medical Education Partnership in Nigeria. She has been a member of the Institute of Medicine, National Academies of Sciences since 2008.

Declaration of Interests

Professor Kanki has received funding or honoraria for lectures, conference attendance, or consultancy from both academia and the US Government but not the pharmaceutical industry. She is a member of the scientific advisory board for Diagnostics for the Real World Ltd.

C. Kirkpatrick (Melbourne, Australia)

Kirkpatrick

Current Positions and Research Interests

Professor Carl Kirkpatrick is Head of Department of Pharmacy Practice and Co-Director of the Centre for Medicine Use and Safety, Monash University, Australia. He received his PhD from the University of Otago (New Zealand) in the area of aminoglycoside pharmacokinetics/pharmacodynamics. Prior to being awarded his PhD, Carl worked as a clinical pharmacist in the area of intensive care and Clinical Pharmacology. Since completing his PhD, his research has focused around the PK/PD of anti-infective agents and other treatments in the critically ill, and the optimisation of dosing in obesity and the renally impaired. His research interests include quantitative clinical pharmacology/pharmacometrics for PK/PD modelling, mechanism-based modelling, clinical pharmacokinetics, therapeutic drug monitoring, and Bayesian Methods for the optimisation of anti-infectives therapy (and other drugs) in difficult patient groups, for example critically ill and cystic fibrosis.

Declaration of Interests

Carl has received no personal support from any industry sources. However, he is involved with collaborative pharmaceutical industry projects with Pfizer and CSL.

R. J. Koerner (Sunderland, UK)

R. J. Koerner (Sunderland, UK)

Current Positions and Research Interests

Roland Koerner is a Consultant Microbiologist at Sunderland Royal Hospital. Together with his colleagues he is responsible for the provision of clinical microbiology and infection control services to City Hospitals Sunderland NHS Foundation Trust. He is also Clinical Senior Lecturer of Newcastle University. His specific clinical interests are diagnosis and management of infection in the critical care setting and optimising antimicrobial chemotherapy by applying PK PD parameters.

Declaration of Interests

Roland Koerner has received sponsorship to attend conferences from Bayer Pharmaceuticals. Some of his students received unconditional educational grants from Pfizer, Bayer and Novartis.

R. E. Lewis (Bologna, Italy)

R lewis

Current Positions and Research Interests

Russell Lewis is an Associate Professor of Medicine in the Department of Medical and Surgical Sciences at the University of Bologna; and he works in the Infectious Diseases Unit at S. Orsola-Malpighi Hospital in Bologna Italy. His research focuses on strategies to improve the management of multidrug-resistant bacterial infections and invasive fungal diseases in immunocompromised patients. He specialises in the pharmacokinetic/ pharmacodynamic analysis of systemic antifungal therapy.

Declarations of Interests

Professor Lewis has received honoraria for lectures from Astellas, Gilead, and Merck; and has received research funding from Pfizer.

J. -Y. Madec (Lyon, France)

J. -Y. Madec (Lyon, France)

Current Positions and Research Interests

Dr Jean-Yves Madec is Research Director at the French Agency for Food, Environmental and Health Safety (ANSES) in Lyon, France. He is the Head of a research group entitled ‘Antimicrobial Resistance and Virulence in Bacteria’ involved in the surveillance of antimicrobial resistance in animals in France. His research interests focus on molecular genetics and epidemiology of resistance in Gram-negative and Gram-positive bacteria of animal origin and issues regarding the animal–human transfer of antimicrobial resistance.

Declaration of Interests

Dr Madec has not received any funding, honoraria or consultancy fees from pharmaceutical companies and has no conflict of interest to declare.

L. Maes (Antwerp, Belgium)

L. Maes (Antwerp, Belgium)

Current Positions and Research Interests

Louis Maes is a veterinarian and, since 2002, a Professor at the University of Antwerp, where he is also director of the Laboratory for Microbiology, Parasitology and Hygiene (http://www.ua.ac.be/lmph). He was previously at the Johnson & Johnson divisions of Janssen Pharmaceutica (Beerse, Belgium) and Tibotec (Mechelen Belgium). His current research interests are antimicrobial drug discovery with particular emphasis on antiparasitics and antimycotics.

Declaration of Interests

Louis Maes currently receives funding for drug screening and evaluation from the World Health Organisation (WHO-TDR) and the Drugs for Neglected Diseases Initiatives (DNDi), and has ad hoc collaborations with pharmaceutical industry partners on a fee-for-service basis (Janssen Pharmacuetica, Barrier Therapeutics). He is currently member of the Belgian Federal Agency for Veterinary Medicines.

J. G. Magee (Newcastle upon Tyne, UK)

Magee

Current Positions and Research Interests

Director of the PHE Public Health Laboratory for the North East of England. Visiting Professor to the University of Newcastle upon Tyne. Member of the National Tuberculosis Programme Board; scientific lead for the North of England Reference Centre for Mycobacteriology. Chair of the HPA/PHE Assay Development Review Group. A member of the International Society for Microbial Systematics.
Research background primarily in diagnostic Mycobacteriology and Taxonomy; most recently in molecular diagnostics and strain typing. Publications show a heavy bias towards these areas, in addition to many presentations to national and international meetings.

Declaration of Interests

Professor John G. Magee has no direct links with any commercial organisation and no conflicts of interest with any other body than his employers and the University of Newcastle upon Tyne.

J.-Y. Maillard (Cardiff, UK)

J. -Y. Maillard (Cardiff, UK)

Current Positions and Research Interests

Jean-Yves Maillard is a Reader in Pharmaceutical Microbiology at the Welsh School of Pharmacy at Cardiff University. His field of expertise concerns biocides; their activity, mechanisms of action and the emergence of microbial resistance and cross-resistance to antimicrobials. He is also working as a consultant for the biocidal industry, through Cardiff University, on matters related to microbicides.

Declaration of Interests

Jean-Yves Maillard's research has mainly been funded by industry and has led to the publication of > 90 articles and 11 book chapters and 1 book, all on biocides.

V. Mallet (Paris, France)

V. Mallet (Paris, France)

Current Positions and Research Interests

Vincent Mallet, MD, PhD is managing senior physician and professor in the Department of Hepatology at Cochin University Hospital in Paris, France (Director Prof. S. Pol). He is Research Director at the Pasteur Institute (Director Prof J Di Santo) in Paris and has founded a company on big-data and health care.

Vincent Mallet has worked on basic and clinical aspects of liver diseases since 1999. His main interests are the burden of HBV, HCV and HEV infections in immunocompromised hosts, the immunopathogenesis of HCV, HBV and HEV infections, novel immunomodulatory therapies for cancer and hepatocellular carcinoma, and big-data to describe the natural courses of diseases.

Declaration of Interests

Vincent Mallet is a speaker for BMS, Gilead, Janssen, Merck and co, a board member of Gilead, Merck and co. and Janssen, and a consultant for Translational Health Economics Network (THEN).

J. Meletiadis (Athens, Greece)

Meletiadis

Current Positions and Research Interests

Dr. Joseph Meletiadis is a Ph.D. mycologist, Lecturer in Mycology at the Medical School of University of Athens and leader of Mycology Unit at the Clinical Microbiology Laboratory of Attikon University General Hospital of Athens, Greece. His main research interests are fungal infections model, molecular diagnostics and identification, antifungal susceptibility testing, pharmacokinetics and pharmacodynamics of antifungal drugs, in vitro and in vivo drug combinations.

Declaration of Interests

Dr. Joseph Meletiadis has received research funding or honoraria for lectures, conference attendance or consultancy from academia and pharmaceutical companies.

J. W. Mouton (Rotterdam, The Netherlands)

Mouton

Current Positions and Research Interests

Johan W. Mouton (MD PhD FIDSA) is Professor of pharmacodynamics and pharmacokinetics of antimicrobials at the Department of Medical Microbiology at the Radboud University Medical Centre, Nijmegen, the Netherlands, and Unit Head Research and Development at the Department of Medical Microbiology and Infectious Diseases at the Erasmus Medical Centre, Rotterdam, the Netherlands. His primary interest is optimizing antimicrobial therapy in patients by establishing pharmacokinetic/pharmacodynamic relationships (PK/PD) of antimicrobials in vitro and in vivo and contributing to guidelines. He is present chair of the Dutch Working Party on Antibiotic Policy, a member of the Dutch expert committee on the use of antimicrobials in animals (SDa) and a steering committee member of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Declaration of Interests

Johan W. Mouton received research funding by means of grants, lecturing and advisory boards from academia, the EU, IMI and various pharmaceutical companies during the last three years, including Astellas, Astra-Zeneca, Basilea, Cubist, Eumedica, Gilead, Merck, Polyphor, Pfizer, Roche and Shionogi.

A. E. Muller (Den Haag, The Netherlands)

Muller

Current Positions and Research Interests

Dr Anouk Muller is a consultant microbiologist and currently works for the department of medical microbiology at the Medical Centre Haaglanden in The Hague (NL). Her main research interests are the pharmacokinetics and pharmacodynamics of antibiotics, in particular various aspects of modelling to improve antimicrobial therapy in patients.

Declarations of Interests

Dr Anouk Muller has received research funding or honoraria for lectures or consultancy from academia and pharmaceutical companies.

T. Parkinson (Sandwich, UK)

T. Parkinson (Sandwich, UK)

Current Positions and Research Interests

Tanya Parkinson is a biologist at Pfizer Global Research and Development, Sandwich Laboratories, Kent. She is responsible for leading drug discovery projects on infectious diseases, currently focusing on neglected tropical diseases such as malaria and Chagas disease. In the past she has also worked on drug discovery for HIV, hepatitis C and fungal infections.

Declaration of Interests

Tanya Parkinson owns shares in Pfizer Ltd.

S. Partridge (Sydney, Australia)

Partridge
Current Positions and Research Interests

Dr Sally Partridge is employed as a Senior Hospital Scientist by the Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, Australia, working in The Westmead Institute for Medical Research, The University of Sydney. She also holds an honorary position as Principal Research Fellow in the Sydney Medical School, The University of Sydney. Her research interests are the genetics (mobile genetic elements, resistance plasmids, bioinformatics) and genetic epidemiology of mobile antibiotic resistance in Gram-negative bacteria, particularly the Enterobacteriaceae.

Declaration of Interests

Dr Sally Partridge has received funding from the Australian National Health and Medical Research Council (NHMRC) as a Chief Investigator on Project grants, the Australian National Data Service (ANDS) and the Australian Society for Microbiology, but not from commercial sources.

M. Peters (San Francisco, USA)

Peters

Current Positions and Research Interests

Dr Peters is a Professor of Medicine and Chief of Hepatology Research at the University of California at San Francisco, where she holds the John V. Carbone, MD, Endowed Chair in Medicine. Her research focuses on viral hepatitis in complicated clinical settings, including patients with HIV infection.
She leads the NIH AIDS Clinical Trial Group, studying therapy of HIV/HBV and HIV/HCV co-infections, and the Women¹s Interagency HIV study Hepatitis Working group.

Declaration of Interests

In 2011 I have consulted for Merck and Biotron. I am on scientific advisory boards for clinical care options and HEPDART. My husband works for Grad, a subsidiary of Roche.

L. Poirel (Fribourg, Switzerland)

Poirel

Current Positions and Research Interests

Dr Laurent Poirel is an Associate Professor at the Medical and Molecular Microbiology Unit, Dept of Medicine, Faculty of Science of the University of Fribourg, Switzerland. His research interests include emerging mechanisms of resistance to ß-lactams and quinolones in Gram-negative rods. He is specialized on the genetics of acquisition of broad-spectrum ß-lactamases in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii , plasmid-mediated quinolone resistance, and polymyxin resistance determinants in Enterobacteriaceae. He is the author of more than 420 publications in international journals and member of several journal editorial boards.

Declaration of Interests

He has occasionally received research funding or honoraria from pharmaceutical companies.

C. F. Pomba (Lisbon, Portugal)

C. F. Pomba (Lisbon, Portugal)

Current Positions and Research Interests

Dr Constança Pomba is Associate Professor of Internal Medicine and Strategies of Antimicrobial Therapy at the Faculty of Veterinary Medicine of the University of Lisbon, Portugal. She heads a research group on Antimicrobial and Biocide Resistance at the Interdisciplinary Animal Health Research Centre. Her major research interests include surveillance of multidrug-resistant bacteria, molecular mechanisms of antimicrobial resistance and antibacterial therapy for multidrug-resistant bacterial infections.

Declaration of Interests

Dr Pomba currently receives research funding from the government and national programmes (Fundação para a Ciência e a Tecnologia). In the past, she has occasionally received research support or honoraria for lectures from pharmaceutical companies including Zoetis and Atral Cipan. She is vice-chair of the Antimicrobial Working Party (AWP) and member of the Antimicrobial Advice ad hoc Expert group (AMEG) of the European Medicines Agency (EMA).

S. Pournaras (Athens, Greece)

S. Pournaras (Larissa, Greece)

Current Positions and Research Interests

Spyros Pournaras is a medical microbiologist. He currently serves as Associate Professor of Medical Microbiology at the Department of Microbiology of the Medical School, University of Athens, Greece. His research interests are primarily antibiotic resistance mechanisms, antibiotic resistance surveillance and molecular epidemiology of multidrug-resistant pathogens. He also serves on the editorial boards of other journals in the field of antimicrobial chemotherapy.

Declaration of Interests

Spyros Pournaras has not received funding or honoraria from commercial organisations.

V. Ricci (Birmingham, UK)

Ricci
Current Positions and Research Interests

Dr Vito Ricci is a Senior Research Fellow at the University of Birmingham. His research interests are in various aspects of antimicrobial resistance especially the molecular mechanisms and regulation of multiple drug resistance in Salmonella enterica. He is a member of the Editorial Board of the Journal of Antimicrobial Chemotherapy .

Declaration of Interests

Dr. Ricci has no conflicts of interest to declare.

K.K. Scarsi (Omaha, USA)

Scarsi

Current Positions and Research Interests

Dr Kim Scarsi is an Associate Professor in the College of Pharmacy, Department of Pharmacy Practice, at the University of Nebraska Medical Center in Omaha, NE, USA. She received her Doctor of Pharmacy degree from Drake University, completed post-graduate residency training at Northwestern Memorial Hospital, received her Master of Science in Clinical Investigation from Northwestern University, and is a Board Certified Pharmacotherapy Specialist with added qualifications in Infectious Diseases. Her research interests include the pharmacology of antiretroviral agents and medications commonly used to treat co-infections with HIV, pharmacologic considerations related to gender and pregnancy, management of HIV-related drug interactions, and evaluation of outcomes related to HIV care and treatment. She serves on the U.S. Department of Health and Human Resources Panel on Antiretroviral Guidelines for Adults and Adolescents.

Declaration of Interests

Dr Scarsi serves as an author for Medscape Ask the Experts. She has not received honoraria or research support from industry sources. Her current grant support is through the National Institutes of Health, both NIAID and NICHD and the U.S. Centers for Disease Control.

C. Sutherland (London, UK)

C. Sutherland

Current Positions and Research Interests

Colin joined LSHTM in 1998 working on the adhesion of Plasmodium falciparum gametocytes. He then coordinated a series of Wellcome Trust-funded clinical trials in Farafenni, The Gambia from 2000 to 2002. These measured the effect of antimalarial combination therapy on transmission of P. falciparum . Since 2004 Colin has been supported by PHE (formally UK Health Protection Agency) and currently has a joint appointment in the PHE's Malaria Reference Laboratory in LSHTM, and the Department of Clinical Parasitology, Hospital for Tropical Diseases, where he is engaged in studies of parasite drug resistance, development of new molecular diagnostics and in studies of the genetics/genomics of all Plasmodium species that infect humans.

Declaration of Interests

Apart from a small consultancy project (USD 38K) from Caridian BCT in 2011, all Colin’s research is funded by not-for-profit organizations, including the PHE, EDCTP, EU FP7, Medicines for Malaria Venture, Wellcome Trust, FIND.

E. Tacconelli (Rome, Italy)

Tacconelli

Current Positions and Research Interests

Dr Tacconelli is an Assistant Professor of Infectious Diseases at Università Cattolica Sacro Cuore in Rome, Italy. In addition to being an Editor for the Journal of Antimicrobial Chemotherapy , she also serves on the editorial boards of other infectious disease journals. Her specific research interests include infection control, epidemiology and clinical aspects of healthcare-associated infections due to antimicrobial-resistant bacteria.

Declaration of Interests

Dr Tacconelli has received funding for research, consultancy, and lecture honoraria from national and academic agencies, as well as pharmaceutical companies. Pharmaceutical companies that have supported her research and/or lectures include Astellas, Novartis, Pfizer, Sanofi-Aventis, and Merck.

B. Taiwo (Chicago, USA)

Taiwo

Current Positions and Research Interests

Dr Babafemi Taiwo is an Infectious Diseases Physician, Teacher and Researcher at the Feinberg School of Medicine, Northwestern University. He is also affiliated with Northwestern University's Center for Global Health. His research interests include optimization of antiretroviral therapy, antiretroviral drug resistance and international health.

Declaration of Interests

Dr Babafemi Taiwo has served as an advisor and/or received research support (to Northwestern University) and honoraria from Janssen, GlaxoSmithKline and ViiV.

A.J. Ullmann (Würzburg, Germany)

Ullmann

Current Positions and Research Interests

Andrew J. Ullmann serves as Professor of Medicine/Infectious Diseases and is Head of Infectious Diseases at Julius-Maximilians University, Wuerzburg, Germany. He is a fellow of the Infectious Diseases Society of America. His major interests include the development of new antimicrobial agents, the management and prevention of infections in immunosuppressed patients especially patients with haematological malignancies and haematopoietic stem cell transplant recipients.

Declaration of Interests

Andrew Ullmann has received research support, honoraria for lectures and consultancy fees from a number of pharmaceutical companies including Astellas, Basilea, Gilead, Merck (MSD and former Schering-Plough), and Pfizer.


D. van Duin (Chapel Hill, USA)

 Van Duin

Current Positions and Research Interests

Dr. van Duin is an Associate Professor of Medicine and the founding Director of the Immunocompromised Host Infectious Diseases Program in the Infectious Diseases Division at the University of North Carolina. His research interests are infections caused by multidrug-resistant Gram-negative bacteria, and infections in immunocompromised patients including burn patients. He has a particular interest in translational research in carbapenemase-producing Enterobacteriaceae.

Declarations of Interests

Dr. van Duin has received research support from the National Institutes of Health. In addition, he has received research support, honoraria for lectures and consultancy fees from a number of pharmaceutical companies including Astellas, Actavis, Sanofi-Pasteur, Scynexis, Steris, Pfizer and Tetraphase.

G. Werner (Wernigerode, Germany)

Werner

Current Positions and Research Interests

Guido Werner works as a Medical Microbiologist in the Department of Infectious Diseases, Robert Koch-Institute, Wernigerode Branch, Germany. He is Head of the Division ‘Nosocomial Pathogens and Antimicrobial Resistances’ and of the National Reference for Staphylococci and Enterococci. He is also Professor for Medical Microbiology and gives lectures on this subject at the Georg-August-University Goettingen and the Technical University Brunswick. His main research interests are in methods of rapid and molecular diagnostics, molecular strain characterization/typing including NGS of bacterial pathogens and all biological and epidemiological aspects of antimicrobial resistance. He has worked for 18 months as a national expert at the European Commission, General Directorate ‘Health and Consumer Protection’ in the Unit ‘Health threats’ (DG SANCO C3) and is the nominated ‘National Microbiology Focal Point’ of a microbiological working group at the European CDC, Stockholm, Sweden. He is a member of several national and international medical societies and amongst others Scientific officer for Public Health of the ESCMID study group on microbial markers ESGEM.

Declaration of Interests

None to declare

H. Wickens (London, UK)

Wickens

Current Positions and Research Interests

Dr Hayley Wickens is a microbiology specialist pharmacist with a background in both clinical practice and research. She is an Honorary Lecturer in the Department of Medicine, Imperial College London and Honorary ID research pharmacist, Imperial College Healthcare NHS Trust. Her research and teaching interests include antibiotic stewardship, pharmaceutical microbiology and monitoring of antibiotic consumption. Hayley also works for the British Society for Antimicrobial Chemotherapy as the UK data co-ordinator for the European Surveillance of Antimicrobial Chemotherapy project.

Declaration of Interests

Hayley Wickens has received funding, honoraria and/or travel expenses for lectures, conference attendance or consultancy from a number of pharmaceutical companies and other organisations including Astellas, AstraZeneca, Basilea, Cubist, Forest, GSK, MSD, Novartis, Pfizer, Quintiles, Roche, Wyeth, UK Clinical Pharmacy Association and British Society for Antimicrobial Chemotherapy.

METHODOLOGICAL ADVISORS

A. J. Hedges (Bristol, UK)

Hedges

Current Positions and Research Interests

Alan Hedges was Senior Lecturer in Bacteriology in the University of Bristol until his retirement, when he was appointed honorary Research Fellow in the School of Cellular & Molecular Medicine.
His research interests are centred on the development of statistical methods and their application to microbiological problems.

Declaration of Interests

None to declare.

T. Lamagni (London, UK)

Lamagni

Current Positions and Research Interests

Theresa Lamagni graduated in Psychology (BSc) in 1994 and came to work for the Public Health Laboratory Service (now Public Health England) Communicable Disease Surveillance Centre in 1995 as a research assistant within the HIV & STI Department. During this time she completed an MSc in Epidemiology at the London School of Hygiene & Tropical Medicine. In May 2001, she joined the newly formed Healthcare Associated Infection & Antimicrobial Resistance Department within the PHE in London as a senior epidemiologist. She completed her PhD on the epidemiology of severe group A streptococcal infections in Europe at the University of Helsinki in 2008. She currently manages the surgical site infection surveillance programme and is involved in a number of national and international projects concerned with developing new surveillance initiatives, research programmes and public health policies.

Declaration of Interests

Theresa Lamagni has no conflicts of interest to declare.

EDITORIAL MANAGER

C. W. E. Drummond
C. W. E. Drummond

Colin has a BSc in Microbiology and Virology from the University of Warwick and an MSc from the University of Oxford. He started his scientific publishing career at the Society for General Microbiology in 1992 as a Staff Editor for the Journal of General Virology . In 1996 he moved to International Medical Press in London, working on the titles International Antiviral News , Antiviral Chemistry and Chemotherapy and Antiviral Therapy . Colin joined JAC as Editorial Manager in 1999.

SENIOR STAFF EDITOR

C. L. Jeeves
C. L. Jeeves

Dr Clare Jeeves is the Senior Staff Editor for JAC . She has a first class honours degree in Molecular Cell Biology from the University of Nottingham (1993-1996) and a PhD in Biochemistry from the University of Birmingham (1996-1999). On completion of her PhD Clare decided to move from research into publishing and spent 2.5 years working for Portland Press in London (working mainly on the Biochemical Journal) before joining JAC in March 2002.

STAFF EDITOR

S. Brockhouse
S. Brockhouse

Suzanne has a BSc in Applied Biology from the University of Bath and a PhD in Behavioural Chemical Ecology from the University of Southampton. After completing her PhD, Suzanne worked for the Society for Experimental Biology on their publication ventures before joining the Company of Biologists Ltd in 2008 where she worked as a Production Editor for The Journal of Experimental Biology . Suzanne joined the JAC Editorial team in September 2010 as a Staff Editor.







Publishers: Sending books for review

Back to top of page

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Subscribe Now